Why Won't the NHS Screen Every Man for Prostate Cancer? The 2026 Decision Explained

Prostate cancer is the most common cancer in men in the UK, and around 12,000 men die from it every year. Women are invited for breast and cervical screening. In May 2026, the UK's screening experts recommended that most men still will not be invited for prostate cancer screening. If that sounds wrong to you, you are not alone. Charities, doctors and campaigners are frustrated. But the reasoning behind the decision is worth understanding, because it affects choices you can make for yourself today, and it does not mean you cannot be tested.

Screening, Testing and Diagnosis Are Not the Same Thing

Much of the confusion comes from a few terms that sound alike but mean very different things.

Population screening is when the NHS proactively invites everyone in a group, such as all men of a certain age, to be tested even though they have no symptoms. Targeted screening invites only people at higher risk. PSA testing is the blood test itself, and it can be used in any of these settings. Informed choice means a man without symptoms can ask his GP for a PSA test after talking through the pros and cons. Diagnostic testing is what happens when you have symptoms or a raised result, and can include an examination, an MRI scan and sometimes a biopsy.

The 2026 decision is about population and targeted screening. It does not remove your ability to ask for a PSA test, and it does not change the tests you are offered if you have symptoms.

What Was Actually Decided?

On 28 May 2026, the UK National Screening Committee published its final recommendation. It backed the UK's first prostate cancer screening programme, but only for a small group: men aged 45 to 61 who carry a BRCA2 gene variant and have a family history of breast, ovarian, pancreatic or prostate cancer. They would be offered a PSA blood test every two years.

The committee's draft, published in November 2025, had also included men with BRCA1 variants. The final version removed them, saying there was not yet enough evidence. It did not recommend screening for the general male population, for men with a family history but no BRCA2 variant, or for Black men.

Recommendations from the committee go to health ministers in each of the four UK nations, who make the final decision on whether and how to introduce screening. If accepted, Cancer Research UK expects roll-out to begin from 2027, although it may take some time to reach every eligible man.

Why the Experts Said No for Most Men

The problem is the test. PSA, or prostate-specific antigen, is a protein made by the prostate. A raised level can be a sign of cancer, but it can also be caused by an enlarged prostate or an infection. And some cancers do not raise it at all.

There is a second problem. Many prostate cancers grow so slowly that they would never cause harm in a man's lifetime. Screening finds lots of these, and some of those men then go on to have biopsies and treatments they did not need. Those treatments can leave men with incontinence and erectile problems.

Weighing all of that, the committee concluded that inviting every man in an age group would put too many at risk of overdiagnosis without giving enough of them the benefit of earlier diagnosis. Men with BRCA2 variants are different: they have a substantially higher risk of prostate cancer, and it is more likely to be fast-growing. For them, the committee judged that the benefits outweigh the harms.

Why So Many People Are Frustrated

The charity Prostate Cancer Research funded an independent technical review of the computer model the committee relied on. That review, by the York Health Economics Consortium, reported significant methodological limitations, including assumptions that did not match how screening would work in practice today. It also said the model left out the MRI-led diagnostic pathways that are now central to clinical practice and help avoid unnecessary biopsies.

The biggest criticism is about Black men. Around 1 in 4 Black men in the UK will get prostate cancer in their lifetime, roughly double the average risk. The committee said there is still too much uncertainty about whether screening would do more good than harm for them, and is waiting for more evidence. Prostate Cancer UK called the decision a step in the right direction, but said many men at the highest risk are being left behind.

It is worth being clear about what this is and is not. It is not a cover-up. The committee's minutes, its model and its critics' reports are all public, and you can read them yourself. It is a genuine, heated disagreement about how to weigh harms against benefits, and about whether the evidence reflects modern diagnosis. In August 2026, the committee said the government is funding the model to be maintained and kept under review for a further three years, and updated as new evidence emerges.

What You Can Do Right Now

No screening programme does not mean no test. In the UK, men aged 50 and over can ask their GP for a PSA test, even without symptoms, and should be given balanced information to help them decide. If you are at higher risk, for example if you are Black or have a family history, UK guidance encourages you to talk to your GP about your risk and testing from 45. In the US and Canada, guidelines also stop short of screening every man, so the conversation with your own doctor matters there too.

Know your family history. Prostate cancer in a father or brother raises your risk, and so does breast or ovarian cancer in the family, especially if a BRCA variant has been found. If a relative has a known BRCA variant, ask your GP whether genetic testing is right for you.

Do not ignore changes. Needing to pee more often, especially at night, a weak flow, or a sudden urgent need to go are most often caused by an enlarged prostate rather than cancer. But they are always worth getting checked, and that is diagnostic testing, which is available whatever the screening decision says. Early prostate cancer often causes no symptoms at all, which is exactly why knowing your risk matters.

If your PSA comes back raised, ask what happens next. In many areas, an MRI scan is now offered before any biopsy. Newer blood tests that combine several markers are also being studied. And the TRANSFORM trial, the biggest prostate screening study in the UK in decades, is designed to answer many of the open questions, especially for Black men.

The screening decision may frustrate you, and that frustration is shared by many experts. But you do not have to wait for a national programme to take your own health seriously. Know your family history, know that you can ask for a PSA test, and speak up about any changes.

This article is intended for informational and educational purposes only and is not medical advice. Screening recommendations differ between countries and may change as ministers make decisions and new evidence emerges; the position described here reflects the sources cited above at the time of writing. If you have urinary symptoms or are concerned about your risk, please speak to your GP.